
==== Front
BMC Oral Health
BMC Oral Health
BMC Oral Health
1472-6831
BioMed Central London

39300425
4894
10.1186/s12903-024-04894-3
Case Report
Monostotic fibrous dysplasia of jaw bones: a case series
http://orcid.org/0000-0002-8576-7897
Hande Alka
http://orcid.org/0000-0002-2492-1643
Kalmegh Padmashri padmashrikalmegh16@gmail.com

http://orcid.org/0000-0002-9278-5786
Patil Swati
http://orcid.org/0000-0001-9225-7919
Sonone Archana
http://orcid.org/0000-0002-0529-3856
Pakhale Aayushi
https://ror.org/03ec9a810 grid.496621.e 0000 0004 1764 7521 Department of Oral & Maxillofacial Pathology and Microbiology, Sharad Pawar Dental College & Hospital, Datta Meghe Institute of Higher Education and Research, Sawangi (Meghe), Wardha, 442004 Maharashtra India
19 9 2024
19 9 2024
2024
24 111912 2 2024
10 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Background

Fibrous dysplasia (FD) is a benign fibro-osseous lesion, a skeletal developmental anomaly of the bone-forming mesenchyme. The diagnosis of fibro-osseous lesions, particularly those of the jaw bones, poses significant challenges to clinicians and pathologists since it requires a correlation of clinical, radiological, histological, and surgical findings. Accurate and specific diagnosis is crucial as treatment modalities differ with different fibro-osseous lesions.

Methods

This retrospective analysis presents a case series of a rare condition of monostotic FD in the maxillofacial region affecting jaw bones diagnosed and/or treated over period of 10 years.

Results

Five cases of monostotic FD were diagnosed and treated between a period of 2013 and 2023. The cases from the 2nd to 8th decade were included in the analysis with equal involvement of males and females. Out of five cases, four cases were involving maxilla and 1 showed involvement of mandible.

Conclusion

FD is a rare entity affecting the jaw bones which often lead to disfigurement of face. Early detection is warranted to decrease potential complications. In addition, genetic analysis could help in understanding the occurrence in certain population.

Highlights

Fibrous dysplasia presents clinically in varied forms which may appear as the collision of different pathologic processes.

We present a case series of a rare condition of monostotic fibrous dysplasia in the maxillofacial region affecting jaw bones- over the period of 10 years of an institutional database.

We discussed the present knowledge on fibrous dysplasia, emphasizing the need to understand its clinical, radiographic, and histological characteristics, as well as essential aspects relevant to differential diagnosis and patient management.

Keywords

Fibro-osseous lesions
Fibrous dysplasia
GNAS1
Monostotic
Polyostotic
Malignant change
Datta Meghe Institute of Higher Education and ResearchOpen access funding provided by Datta Meghe Institute of Higher Education and Research.

issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

The term “benign fibro-osseous lesions” (BFOLs) refers to a wide variety of pathologic disorders that include developmental lesions, reactive or dysplastic diseases, and neoplasms [1]. Fibrous dysplasia (FD), cemento-osseous dysplasia, and ossifying fibroma are some of the most prevalent fibro-osseous lesions [2]. Regardless of subtype, all BFOLs indicate fibrous connective tissue replacement of normal bone with an admixture of mineralized tissue, including osteoid, mature bone, and/or cementum-like calcifications [3]. FD is a hamartomatous, non-neoplastic developmental defect of unknown origin in which normal bone is replaced by an aberrant proliferation of cellular fibrous connective tissue intermixed with varying bony trabeculae [4, 5]. Von Recklinghausen first discovered “osteitis fibrosa generalisata” in 1891 in a patient with skeletal abnormalities caused by fibrotic bone alterations. In 1938, Lichtenstein first used the term “fibrous dysplasia” to describe the condition [6]. Fibro-osseous dysplasia and fibrous osteodysplasia are two terms that can be used interchangeably to describe FD [7]. Reed characterises the condition as “arrest of bone maturation in woven bone with ossification caused by nonspecific fibro-osseous metaplasia” [8]. Schlumberger defined the disease process as “monostotic fibrous dysplasia” when it originally involved a single bone [9]. FD accounts for approximately 2.5% of all bone lesions and 7% of benign bone tumors, with a prevalence of 1:4000-1:10,000 incidence [10]. This rare benign skeletal condition shows involvement of one or more bones that is monostotic or polyostotic respectively. Polyostic form is further classified into 3 subtypes i) “ Multiple-bone Jaffe-Lichtenstein ”, which is sometimes associated with “café au lait” pigmentation (coffee with milk) (ii) “McCune-Albright’s syndrome” is distinguished by widespread involvement of skeleton, café au lait pigmentation, and a number of endocrinopathies, the most frequent precocious puberty (iii) Mazabraud syndrome which is characterized by polyostotic FD and intramuscular myxomas. During the phase of growth and maturation of body mostly FD remains dormant and there is burnout phase during early adulthood (late adolescence or early twenties), corresponds with growth milestones [11]. Overproduction of the enzyme tyrosinase, which is the rate-limiting step in melanin production, results in café-au-lait spots [12]. The ratio of polyostotic to monostotic forms varies between 8:1 and 10:1 respectively [13]. Facial and cranial bones are involved in about 50% of patients with polyostotic FD and 10–27% of patients with monostotic FD [14]. In the monostotic FD the femur, tibia, ribs, calvaria, skull base, and in orofacial bones, zygoma, maxilla and mandible are commonly affected. Amongst the jaw bones in 50% of patients, the maxilla is more commonly affected than the mandible [15, 16]. The majority of these lesions are unilateral affecting the posterior region [7]. In addition to monostotic and polyostotic FD, “craniofacial FD” is a presentation in which the lesions are confined to adjacent bones of the craniofacial skeleton [17]. Craniofacial FD is not totally monostotic due to the involvement of several contiguous craniofacial skeleton bones, but it is also not truly polyostotic because bones other than the craniofacial complex are not frequently involved [18]. Both endochondral and desmal ossifying bones can develop FD. The most common symptom of craniofacial FD is prominent swelling in the affected area [19]. Its onset is frequently associated with rapid skeletal growth and exhibits a self-limiting pattern, because once bone growth ceases, FD becomes more quiescent or static. The most typical presenting characteristic of monostotic FD is painless expansion in the affected region, however, it can occasionally progress rapidly [20]. The monostotic type affects both sexes equally, but the polyostotic variant has a female predilection [21]. Because of the oestrogen receptors identified in FD, female patients have elevated pain levels during pregnancy and the menstrual cycle [22].

Methods

The retrospective analysis of institutional medical records from 2013 to 2023 were reviewed for FD cases. Ethical approval was obtained from the IEC. Demographic details, medical, dental history of each case were retrieved from the database. Further, radiographic and histopathology features of case were reviewed again to rule out any other diagnosis. Treatment, disease progression and follow-up information were also gathered. In 2023, a 16-year-old male patient reported with painless swelling on the right side of maxillary bone in the posterior aspect that had been present for 3 years. History of the present illness reveals that 3 years ago, the patient first observed small growth over the right maxillary alveolar region. The swelling gradually grew in present size over the course of 3 years. Extraorally, the face was clinically asymmetrical due to swelling on the affected right side. Intraorally, the right side of the alveolus had enlarged, measuring roughly 4 × 2 cm in size (Fig. 1). The enlargement was firm and non-tender on palpation. No historyof trauma or tooth loosening was there. There was no swelling anywhere on the body, and there were no café au lait spots either. The investigations include a complete blood count, blood calcium, serum total alkaline phosphatase (ALP), and a panoramic radiograph. All the parameters, with the exception of ALP, were within normal ranges. ALP levels have risen to 300 U/L. An incisional biopsy of the maxillary lesion had been carried out and processed for histopathological examination. A macroscopic examination of biopsy tissue revealed a single piece of firm tissue that was creamish white in color and size of 1 × 0.8 × 0.4 cm. Depending on the clinical history, radiographic evaluation, and histological features of the lesion the diagnosis of monostotic fibrous dysplasia (FD) was made. Post diagnosis the patient was posted for surgical management. Further a retrospective analysis of 5 cases diagnosed with monostotic FD in a tertiary healthcare center was conducted, with clinical findings, radiological characteristics, histological features, and biochemical analysis like serum alkaline phosphatase. All pertinent data from each patient was collected and tabulated (Table 1). Among the 5 cases, the disease was restricted to the maxilla in 4 cases (Figs. 1, 2, 3 and 4), whereas 1 case showed mandibular involvement (Fig. 5). There was no history of pain in any of the cases. All the included cases were from the 2nd to 8th decade of life. In context to gender predilection, females and males were equally affected in the ratio of 1:1. The age range of all cases were between 16 and 80 years. The broad age range among people may simply indicate the duration at which the lesions were first noticed and identified, rather than a later age of onset of growth. Because most cases of FD are gradual in the beginning, painless, and asymptomatic throughout delayed reporting by the patient which results in a late diagnosis of the lesion. The level of ALP in all patients was significantly greater than the normal range (Normal range – 38–126 U/L). To the best of our knowledge, this report may be the first case series that provides comprehensive, epidemiological, and clinicopathological insight into craniomaxillofacial FD in Central India, which will significantly contribute to the literature on this rare disorder.

Table 1 Patient details

Sr. No.	Age/
Sex	Area of chief complaint	Size	Radiographic features	Histopathologic features	Alkaline phosphatase level
(Normal range – 38–126 U/L)	Treatment modalities	
Patient 1

(Fig. 1)

	16/M	Upper right anterior alveolus	4 × 2 cm	Radio-opaque lesion	• Lesion in the mature phase

• Curvilinear trabeculae

• Osteoblastic rimming is absent

	300 U/L	Surgical excision	
Patient 2

(Fig. 2)

	50/F	Upper right posterior alveolus	4.5 × 4 cm	Radiolucent lesion	• A lesion in the immature phase

• Osteocytes are large and collagen fibers of trabeculae are seen extending out into fibrous tissue

• Wide osteoids seen in some places

• Connective tissue stroma composed of blood vessels and fibroblasts

• Osteoblastic rimming is absent

	305 U/L	Radical excision and reconstruction	
Patient 3

(Fig. 3)

	80/M	Mid

palatine region

	1.8 × 1.2 cm	Radiolucent lesion	• A lesion in the immature phase

• Increased number of osteocytes

• Open faced active stellate-shaped osteoblasts scattered in fibrous tissue suggest functioning in new bone formation

• Osteoblastic rimming is absent

	196 U/L	Under treatment with bisphosphonate therapy and follow up	
Patient 4

(Fig. 4)

	50/M	Upper right posterior alveolus	1.5 × 1 cm	A radiolucent lesion with areas of radiopacity	• Lesion in mixed-phase

• Reduced number of osteocytes

• Osteoblastic rimming is absent

	162 U/L	Under treatment with bisphosphonate therapy and follow up	
Patient 5

(Fig. 5)

	44/M	Lower left alveolus	3 × 2 cm	Radiolucent lesion	• A lesion in the immature phase

• More number of osteocytes

• Bony trabeculae of coarse and woven bone

Osteoblastic rimming is absent

	417 U/L	Conservative bone shaving	

Fig. 1 (A) Intraoral swelling (B) Orthopantomogram (OPG) showing radioopaque lesion (C) Hematoxylin and Eosin (H & E) staining under low power view (D) H & E staining under high power view

Fig. 2 (A) Intraoral swelling (B) Orthopantomogram (OPG) showing radiolucent lesion (C) Hematoxylin and Eosin (H & E) staining under low power view (D) H & E staining under high power view

Fig. 3 (A) Intraoral swelling (B) Orthopantomogram (OPG) showing radiolucent lesion (C) Hematoxylin and Eosin (H & E) staining under low power view (D) H & E staining under high power view

Fig. 4 (A) Intraoral swelling (B) Orthopantomogram (OPG)  showing radiolucent lesion with areas of radiopacity  (C) Hematoxylin and Eosin (H & E) staining under low power view (D) H & E staining under high power view

Fig. 5 (A) Intraoral swelling (B) Orthopantomogram (OPG)  showing radiolucent lesion (C) Hematoxylin and Eosin (H & E) staining under low power view (D) H & E staining under high power view

Discussion

The cause of FD is unknown; however, it is anticipated to be a genetic predisposition [7]. The postnatal development of FD does not reflect the embryonic phase during which the genetic change occurred. But it depicts the period when the dynamic balance of genetically altered and normal osteogenic cells occurred [23]. Based on the period of time and pattern of the pathogenic mutations, as well as the type of pluripotent cells that mutate during early embryonic development, FD is believed to be an anomaly of pluripotent embryonic cells [24]. All manifestations of the disease have been linked to two mutations. The mutations in codon 201 replace the arginine residue with cysteine, histidine, or, other amino acids in rare cases. The disease-causing mutations occur postzygotically. This explains why the disease is never inherited and why affected individuals exhibit somatic mosaics [25, 26]. The mutation is assumed to be postzygotic, episodic, and located on the GNAS1 gene (Guanine Nucleotide Binding Protein, Alpha Stimulating). This gene on “chromosome 20q13” is responsible for the production of the “alpha subunit of stimulating G-proteins”. This mutation activates adenylate cyclase, which raises intracellular cyclic adenosine monophosphate (AMP) levels, leading to aberrant osteoblast differentiation and the development of metaplastic bone [7]. When the GS gene (GNAS1) is mutated, it is linked to the FD disease spectrum [27]. The increase in stimulatory G protein activity in osteoblast progenitor cells has been proposed to be the outcome of increased proliferation and aberrant differentiation [28]. The mutations in GNAS1 were not observed in cementoosseous dysplasia, ossifying fibromas, or normal bone, indicating that the mutation is specific to FD [20].

Furthermore, studies have indicated the role of the WNT/-catenin signaling pathway in FD [12]. Bone markers are used to evaluate disease activity and response to therapy. The typical markers in FD include ALP and hydroxyproline (OHP). ALP is reported to be elevated in approximately 75% of patients, with the level being linked with severity and activity of the disease [29]. The concentration of ALP may be a significant marker for detecting the recurrence of FD in an early stage. ALP levels are much greater in individuals with craniofacial FD and may be an effective marker to assess cancer progression in it [30]. Patients with FD may also have higher levels of osteocalcin (OC), deoxypyridinoline (D-Pyr), and the C-telopeptide of type I collagen breakdown products (CTX) [31]. The bone matrix in FD is deficient in osteopontin and bone sialoprotein (BSP) as compared to normal bone. BSP is an osteoblastic cell differentiation marker that is necessary for mineralization [29, 32]. The FD-associated phosphate degeneration results from abnormal osteogenic precursors overproducing Fibroblast growth factor-23 (FGF23), which is secreted by both osteoblasts and osteocytes in normal bone [33].

Histopathological spectrum

Microscopically, fibro-osseous lesions are distinguished by the occurrence of varied dense collagenous tissue adjacent to osseous trabeculae; nevertheless, the stage of development of the FD has a considerable impact on the microscopic presentation. As aforementioned, a more immature and radiolucent lesion has an increased proportion of fibrous tissue, whereas as the lesion becomes more mature and radiopaque, the proportion of fibrous tissue is decreased and osseous trabeculae dominates [34]. FD is regarded to be an impeded maturation at the woven bone stage [35]. There are three primary histologic patterns of FD: the classic “ Chinese letter ”, the “ pagetoid type ”, and the “ hypercellular ” type [36, 37]. As per literature review these various microscopic features are site-specific, or the variations may be due to mechanical stress. The discrepancies among these histologic types are beyond the scope of this article and have no bearing on patient prognosis [38]. Microscopic identification of fibro-osseous conditions is difficult because of the overlapping histological characteristics of ossifying fibroma, osseous dysplasia, and FD. Therefore FD should be differentiated from simple bone cysts, ossifying fibromas, adamantinoma, low-grade intramedullary osteosarcoma, and Paget’s disease. The simultaneous assessment of clinical, radiographic, and microscopic findings is the gold standard for diagnosing fibro-osseous lesions [20].

The modalities used in the examination of FD include conventional radiography, computed tomography (CT), magnetic resonance imaging (MRI), and bone scintigraphy [39]. The radiographic characteristics of FD vary depending on the ratio of fibrous tissue to mineralized bone in the lesion [40]. Early FD can be unilocular or multilocular radiolucency, and have borders that are either poorly or clearly delineated. FD contains mottled radiopaque patterns with ill-defined borders that blend into normal surrounding bone [23].

Spontaneous malignant transformation of FD is extremely rare, with incidences as low as 0.93% which includes mesenchymal malignancies like osteosarcomas, fibrosarcomas, and chondrosarcomas [20]. Patients with polyostotic FD are more likely to have malignant transformation than patients with monostotic FD [13]. There is currently no treatment available to prevent disease progression or malignant transformation [12].

The clinical history, demographic data, radiological, and histopathologic findings are the important criteria used to make the diagnosis of FD [29]. In case of the challenges for lesional biopsy due to the location of involvement, age, or other considerations (particularly in polyostotic FD or McCune-Albright’s syndrome), radiographic and clinical findings may be required to confirm the diagnosis [39]. Immunohistochemistry is used in the diagnosis of FD to rule out the possibility of a malignant lesion with a significant history. Polymerase chain reaction and other genetic amplification techniques can now be utilized for screening for gene mutations such as GNAS mutation which is beneficial for confirming a diagnosis [22, 41].

The only treatment for FD is to maintain the optimal density of bones by nutrition, physical activity, and therapeutic pharmaceuticals [12]. The recommended treatment includes: (i) observation (ii) medical intervention (iii) surgery (iv) radical eradication and reconstruction [42]. The embracement of bisphosphonates as a treatment resulted from a better understanding of the etiology of this illness. It inhibits osteoclast activity by binding to bone surfaces, particularly those undergoing active resorption, acting as a biochemical barrier to bone resorption [43]. Posnick and Costello recommended lifelong continuous follow-up for FD [10, 44]. Recurrence of FD is uncommon in adults but more prevalent during adolescence [45].

Conclusion

FD can present clinically in varied forms which may appear as the collision of different pathologic processes. Currently, treatment for FD is limited, but with a greater understanding of the pathophysiology, we may be able to effectively manage these individuals. Even though the prognosis for FD is favourable, a risk of malignant transformation exists. The likelihood of a recurrence or continued growth of the lesion necessitates a long-term follow-up. With advances in molecular pathology, we now have a better knowledge of the pathophysiology of FD. This review outlines present knowledge on FD, emphasizing the need to understand its molecular pathogenesis alongside its clinical, radiographic, and histological characteristics, as well as essential aspects relevant to differential diagnosis and patient management.

Acknowledgements

We acknowledge the support of laboratory technicians from the Department of Oral & Maxillofacial Pathology and Microbiology, Sharad Pawar Dental College & Hospital, Datta Meghe Institute of Higher Education and Research, Sawangi (Meghe), Wardha - 442004, Maharashtra, India.

Author contributions

Dr. Alka Hande - Manuscript review Dr. Padmashri Kalmegh - Manuscript preparation Dr. Swati Patil - Data analysis and interpretation Dr. Archana Sonone - Data acquisition and algorithms Dr. Aayushi Pakhale - Study concepts and design,

Funding

Not applicable.

Open access funding provided by Datta Meghe Institute of Higher Education and Research.

Data availability

All data generated or analysed during this study are included in this published article.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent

Written and informed consent for publication of their clinical details and clinical images was obtained from the patient.

Competing interests

The authors declare no competing interests.

Abbreviations

FD Fibrous dysplasia

ALP Serum total bone alkaline phosphatase

U/L Units per liter

WNT Wingless-related integration site

GNAS1 Guanine Nucleotide binding protein, alpha stimulating

BFOLs Benign fibro-osseous lesions

AMP Cyclic adenosine monophosphate

BMSC Bone marrow stromal cells

IL–6 Interleukin–6

OHP Urine hydroxyproline

OC Osteocalcin

D–Pyr Urine deoxypyridinoline

CTX C-telopeptide of type I collagen breakdown products

BSP Bone sialoprotein

FGF23 Fibroblast growth factor–23

CT Computed tomography

MRI Magnetic resonance imaging

CD117 Cluster of Differentiation 117

OPG Orthopantomogram

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Alawi F. Benign fibro-osseous diseases of the maxillofacial bones. A review and differential diagnosis. Am J Clin Pathol. 2002 Dec;118 Suppl:S50-70.
2. Anitha N Sankari SL Malathi L Karthick R Fibrous dysplasia-recent concepts J Pharm Bioallied Sci 2015 7 Suppl 1 S171 2 10.4103/0975-7406.155892 26015701
Anitha N, Sankari SL, Malathi L, Karthick R. Fibrous dysplasia-recent concepts. J Pharm Bioallied Sci. 2015;7(Suppl 1):S171–2.26015701
3. Brannon RB Fowler CB Benign fibro-osseous lesions: a review of current concepts Adv Anat Pathol 2001 8 3 126 43 10.1097/00125480-200105000-00002 11345237
Brannon RB, Fowler CB. Benign fibro-osseous lesions: a review of current concepts. Adv Anat Pathol. 2001;8(3):126–43.11345237
4. Chandavarkar V Patil PM Bhargava D Mishra MN A rare case report of craniofacial fibrous dysplasia J Oral Maxillofac Pathol 2018 22 3 406 9 10.4103/jomfp.JOMFP_211_18 30651688
Chandavarkar V, Patil PM, Bhargava D, Mishra MN. A rare case report of craniofacial fibrous dysplasia. J Oral Maxillofac Pathol. 2018;22(3):406–9.30651688
5. Abdelkarim A Green R Startzell J Preece J Craniofacial polyostotic fibrous dysplasia: a case report and review of the literature Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008 106 1 e49 55 10.1016/j.tripleo.2008.03.023 18585612
Abdelkarim A, Green R, Startzell J, Preece J. Craniofacial polyostotic fibrous dysplasia: a case report and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;106(1):e49–55.18585612
6. LICHTENSTEIN L. POLYOSTOTIC FIBROUS DYSPLASIA Arch Surg 1938 36 5 874 98 10.1001/archsurg.1938.01190230153012
Lichtenstein L. Polyostotic fibrous dysplasia. Arch Surg. 1938;36(5):874–98.
7. Menon S Venkatswamy S Ramu V Banu K Ehtaih S Kashyap VM Craniofacial fibrous dysplasia: surgery and literature review Ann Maxillofac Surg 2013 3 1 66 71 10.4103/2231-0746.110088 23662263
Menon S, Venkatswamy S, Ramu V, Banu K, Ehtaih S, Kashyap VM. Craniofacial fibrous dysplasia: surgery and literature review. Ann Maxillofac Surg. 2013;3(1):66–71.23662263
8. Reed RJ Fibrous dysplasia of bone. A review of 25 cases Arch Pathol 1963 75 480 95 13973557
Reed RJ. Fibrous dysplasia of bone. A review of 25 cases. Arch Pathol. 1963;75:480–95.13973557
9. Schlumberger HG Fibrous dysplasia of single bones (monostotic fibrous dysplasia) Mil Surg 1946 99 5 504 27 20276798
Schlumberger HG. Fibrous dysplasia of single bones (monostotic fibrous dysplasia). Mil Surg. 1946;99(5):504–27.20276798
10. Ricalde P Horswell BB Craniofacial fibrous dysplasia of the fronto-orbital region: a case series and literature review J Oral Maxillofac Surg 2001 59 2 157 67 10.1053/joms.2001.20487 11213984
Ricalde P, Horswell BB. Craniofacial fibrous dysplasia of the fronto-orbital region: a case series and literature review. J Oral Maxillofac Surg. 2001;59(2):157–67. discussion 167–168.11213984
11. Jeyaraj CP Srinivas CV Craniofacial and monostotic variants of fibrous dysplasia affecting the maxillofacial region J Oral Maxillofacial Surg Med Pathol 2014 26 3 424 31 10.1016/j.ajoms.2013.05.011
Jeyaraj CP, Srinivas CV. Craniofacial and monostotic variants of fibrous dysplasia affecting the maxillofacial region. J Oral Maxillofacial Surg Med Pathol. 2014;26(3):424–31.
12. Riddle ND Bui MM Fibrous dysplasia Arch Pathol Lab Med 2013 137 1 134 8 10.5858/arpa.2012.0013-RS 23276185
Riddle ND, Bui MM. Fibrous dysplasia. Arch Pathol Lab Med. 2013;137(1):134–8.23276185
13. Gbujie IO Dahillo EA Fulorunso DF Nwankwo BE Quadri OR Egbe BI Surgical Treatment of Monostotic Craino-Facial Fibrous Dysplasia: changing the narratives Int J Otolaryngol Head Neck Surg 2021 10 1 49 59 10.4236/ijohns.2021.101006
Gbujie IO, Dahillo EA, Fulorunso DF, Nwankwo BE, Quadri OR, Egbe BI, et al. Surgical Treatment of Monostotic Craino-Facial Fibrous Dysplasia: changing the narratives. Int J Otolaryngol Head Neck Surg. 2021;10(1):49–59.
14. Kim DD Ghali GE Wright JM Edwards SP Surgical treatment of giant fibrous dysplasia of the mandible with concomitant craniofacial involvement J Oral Maxillofac Surg 2012 70 1 102 18 10.1016/j.joms.2011.01.023 21636197
Kim DD, Ghali GE, Wright JM, Edwards SP. Surgical treatment of giant fibrous dysplasia of the mandible with concomitant craniofacial involvement. J Oral Maxillofac Surg. 2012;70(1):102–18.21636197
15. Chen Y Ding X Yang Y Yan W Chen D Li Z Craniofacial fibrous dysplasia associated with McCune-Albright syndrome J Oral Maxillofac Surg 2009 67 3 637 44 10.1016/j.joms.2008.01.068 19231793
Chen Y, Ding X, Yang Y, Yan W, Chen D, Li Z. Craniofacial fibrous dysplasia associated with McCune-Albright syndrome. J Oral Maxillofac Surg. 2009;67(3):637–44.19231793
16. Assaf AT Benecke AW Riecke B Zustin J Fuhrmann AW Heiland M Craniofacial fibrous dysplasia (CFD) of the maxilla in an 11-year old boy: a case report J Craniomaxillofac Surg 2012 40 8 788 92 10.1016/j.jcms.2012.02.016 22436487
Assaf AT, Benecke AW, Riecke B, Zustin J, Fuhrmann AW, Heiland M, et al. Craniofacial fibrous dysplasia (CFD) of the maxilla in an 11-year old boy: a case report. J Craniomaxillofac Surg. 2012;40(8):788–92.22436487
17. Daves ML Yardley JH Fibrous dysplasia of bone Am J Med Sci 1957 234 5 590 606 10.1097/00000441-195711000-00009 13487570
Daves ML, Yardley JH. Fibrous dysplasia of bone. Am J Med Sci. 1957;234(5):590–606.13487570
18. Cohen MM Howell RE Etiology of fibrous dysplasia and McCune-Albright syndrome Int J Oral Maxillofac Surg 1999 28 5 366 71 10.1016/S0901-5027(99)80085-X 10535539
Cohen MM, Howell RE. Etiology of fibrous dysplasia and McCune-Albright syndrome. Int J Oral Maxillofac Surg. 1999;28(5):366–71.10535539
19. Pollandt K Engels C Werner M Delling G Fibröse Dysplasie Pathologe 2002 23 5 351 6 10.1007/s00292-002-0553-1 12376860
Pollandt K, Engels C, Werner M, Delling G. Fibröse Dysplasie Pathologe. 2002;23(5):351–6.12376860
20. Pereira TDSF Gomes CC Brennan PA Fonseca FP Gomez RS Fibrous dysplasia of the jaws: integrating molecular pathogenesis with clinical, radiological, and histopathological features J Oral Pathol Med 2019 48 1 3 9 10.1111/jop.12797 30376190
Pereira TDSF, Gomes CC, Brennan PA, Fonseca FP, Gomez RS. Fibrous dysplasia of the jaws: integrating molecular pathogenesis with clinical, radiological, and histopathological features. J Oral Pathol Med. 2019;48(1):3–9.30376190
21. Speight PM Carlos R Maxillofacial fibro-osseous lesions Curr Diagn Pathol 2006 12 1 1 10 10.1016/j.cdip.2005.10.002
Speight PM, Carlos R. Maxillofacial fibro-osseous lesions. Curr Diagn Pathol. 2006;12(1):1–10.
22. DiCaprio MR Enneking WF Fibrous dysplasia. Pathophysiology, evaluation, and treatment J Bone Joint Surg Am 2005 87 8 1848 64 16085630
DiCaprio MR, Enneking WF. Fibrous dysplasia. Pathophysiology, evaluation, and treatment. J Bone Joint Surg Am. 2005;87(8):1848–64.16085630
23. Feller L Wood NH Khammissa RAG Lemmer J Raubenheimer EJ The nature of fibrous dysplasia Head Face Med 2009 5 22 10.1186/1746-160X-5-22 19895712
Feller L, Wood NH, Khammissa RAG, Lemmer J, Raubenheimer EJ. The nature of fibrous dysplasia. Head Face Med. 2009;5:22.19895712
24. Riminucci M Saggio I Robey PG Bianco P Fibrous dysplasia as a stem cell disease J Bone Min Res 2006 21 Suppl 2 P125 131 10.1359/jbmr.06s224
Riminucci M, Saggio I, Robey PG, Bianco P. Fibrous dysplasia as a stem cell disease. J Bone Min Res. 2006;21(Suppl 2):P125–131.
25. Bianco P Kuznetsov SA Riminucci M Fisher LW Spiegel AM Robey PG Reproduction of human fibrous dysplasia of bone in immunocompromised mice by transplanted mosaics of normal and gsalpha-mutated skeletal progenitor cells J Clin Invest 1998 101 8 1737 44 10.1172/JCI2361 9541505
Bianco P, Kuznetsov SA, Riminucci M, Fisher LW, Spiegel AM, Robey PG. Reproduction of human fibrous dysplasia of bone in immunocompromised mice by transplanted mosaics of normal and gsalpha-mutated skeletal progenitor cells. J Clin Invest. 1998;101(8):1737–44.9541505
26. Ippolito E Bray EW Corsi A De Maio F Exner UG Robey PG Natural history and treatment of fibrous dysplasia of bone: a multicenter clinicopathologic study promoted by the European Pediatric Orthopaedic Society J Pediatr Orthop B 2003 12 3 155 77 12703030
Ippolito E, Bray EW, Corsi A, De Maio F, Exner UG, Robey PG, et al. Natural history and treatment of fibrous dysplasia of bone: a multicenter clinicopathologic study promoted by the European Pediatric Orthopaedic Society. J Pediatr Orthop B. 2003;12(3):155–77.12703030
27. Youssoufian H Pyeritz RE Mechanisms and consequences of somatic mosaicism in humans Nat Rev Genet 2002 3 10 748 58 10.1038/nrg906 12360233
Youssoufian H, Pyeritz RE. Mechanisms and consequences of somatic mosaicism in humans. Nat Rev Genet. 2002;3(10):748–58.12360233
28. Alves N de Oliveira RJ Takehana D Deana NF Recurrent Monostotic Fibrous Dysplasia in the Mandible Case Rep Dent 2016 2016 3920850 27340572
Alves N, de Oliveira RJ, Takehana D, Deana NF. Recurrent Monostotic Fibrous Dysplasia in the Mandible. Case Rep Dent. 2016;2016:3920850.27340572
29. Chapurlat RD Meunier PJ Fibrous dysplasia of bone Best Pract Res Clin Rheumatol 2000 14 2 385 98 10.1053/berh.1999.0071
Chapurlat RD, Meunier PJ. Fibrous dysplasia of bone. Best Pract Res Clin Rheumatol. 2000;14(2):385–98.
30. Park BY Cheon YW Kim YO Pae NS Lee WJ Prognosis for craniofacial fibrous dysplasia after incomplete resection: age and serum alkaline phosphatase Int J Oral Maxillofac Surg 2010 39 3 221 6 10.1016/j.ijom.2009.12.008 20083386
Park BY, Cheon YW, Kim YO, Pae NS, Lee WJ. Prognosis for craniofacial fibrous dysplasia after incomplete resection: age and serum alkaline phosphatase. Int J Oral Maxillofac Surg. 2010;39(3):221–6.20083386
31. Liens D Delmas PD Meunier P Long-term effects of intravenous pamidronate in fibrous dysplasia of bone Lancet 1994 343 8903 953 4 10.1016/S0140-6736(94)90069-8 7909013
Liens D, Delmas PD, Meunier P. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet. 1994;343(8903):953–4.7909013
32. Abdel-Wanis ME Tsuchiya H Melatonin deficiency and fibrous dysplasia: might a relation exist? Med Hypotheses 2002 59 5 552 4 10.1016/S0306-9877(02)00251-7 12376077
Abdel-Wanis ME, Tsuchiya H. Melatonin deficiency and fibrous dysplasia: might a relation exist? Med Hypotheses. 2002;59(5):552–4.12376077
33. Boyce AM Bhattacharyya N Collins MT Fibrous dysplasia and fibroblast growth Factor-23 regulation Curr Osteoporos Rep 2013 11 2 65 71 10.1007/s11914-013-0144-5 23532406
Boyce AM, Bhattacharyya N, Collins MT. Fibrous dysplasia and fibroblast growth Factor-23 regulation. Curr Osteoporos Rep. 2013;11(2):65–71.23532406
34. Waldron CA Fibro-osseous lesions of the jaws J Oral Maxillofac Surg 1993 51 8 828 35 10.1016/S0278-2391(10)80097-7 8336219
Waldron CA. Fibro-osseous lesions of the jaws. J Oral Maxillofac Surg. 1993;51(8):828–35.8336219
35. Yasuoka T Takagi N Hatakeyama D Yokoyama K Fibrous dysplasia in the maxilla: possible mechanism of bone remodeling by calcitonin treatment Oral Oncol 2003 39 3 301 5 10.1016/S1368-8375(02)00037-4 12618204
Yasuoka T, Takagi N, Hatakeyama D, Yokoyama K. Fibrous dysplasia in the maxilla: possible mechanism of bone remodeling by calcitonin treatment. Oral Oncol. 2003;39(3):301–5.12618204
36. Chapurlat RD Orcel P Fibrous dysplasia of bone and McCune–Albright syndrome Best Pract Res Clin Rheumatol 2008 22 1 55 69 10.1016/j.berh.2007.11.004 18328981
Chapurlat RD, Orcel P. Fibrous dysplasia of bone and McCune–Albright syndrome. Best Pract Res Clin Rheumatol. 2008;22(1):55–69.18328981
37. Riminucci M Liu B Corsi A Shenker A Spiegel AM Robey PG The histopathology of fibrous dysplasia of bone in patients with activating mutations of the Gs alpha gene: site-specific patterns and recurrent histological hallmarks J Pathol 1999 187 2 249 58 10.1002/(SICI)1096-9896(199901)187:2<249::AID-PATH222>3.0.CO;2-J 10365102
Riminucci M, Liu B, Corsi A, Shenker A, Spiegel AM, Robey PG, et al. The histopathology of fibrous dysplasia of bone in patients with activating mutations of the Gs alpha gene: site-specific patterns and recurrent histological hallmarks. J Pathol. 1999;187(2):249–58.10365102
38. Maki M Saitoh K Horiuchi H Morohoshi T Fukayama M Machinami R Comparative study of fibrous dysplasia and osteofibrous dysplasia: histopathological, immunohistochemical, argyrophilic nucleolar organizer region and DNA ploidy analysis Pathol Int 2001 51 8 603 11 10.1046/j.1440-1827.2001.01252.x 11564214
Maki M, Saitoh K, Horiuchi H, Morohoshi T, Fukayama M, Machinami R. Comparative study of fibrous dysplasia and osteofibrous dysplasia: histopathological, immunohistochemical, argyrophilic nucleolar organizer region and DNA ploidy analysis. Pathol Int. 2001;51(8):603–11.11564214
39. Ricalde P Magliocca KR Lee JS Craniofacial Fibrous Dysplasia Oral Maxillofac Surg Clin N Am 2012 24 3 427 41 10.1016/j.coms.2012.05.004
Ricalde P, Magliocca KR, Lee JS. Craniofacial Fibrous Dysplasia. Oral Maxillofac Surg Clin N Am. 2012;24(3):427–41.
40. Grasso DL Guerci VI Di Emidio P De Vescovi R Ukmar M Cattaruzzi E Dizziness as presenting symptom of monostotic fibrous dysplasia Int J Pediatr Otorhinolaryngol Extra 2006 1 2 138 41 10.1016/j.pedex.2006.03.003
Grasso DL, Guerci VI, Di Emidio P, De Vescovi R, Ukmar M, Cattaruzzi E, et al. Dizziness as presenting symptom of monostotic fibrous dysplasia. Int J Pediatr Otorhinolaryngol Extra. 2006;1(2):138–41.
41. Dumitrescu CE Collins MT McCune-Albright syndrome Orphanet J Rare Dis 2008 3 1 12 10.1186/1750-1172-3-12 18489744
Dumitrescu CE, Collins MT. McCune-Albright syndrome. Orphanet J Rare Dis. 2008;3(1):12.18489744
42. Mäkitie AA Törnwall J Mäkitie O Bisphosphonate treatment in craniofacial fibrous dysplasia—a case report and review of the literature Clin Rheumatol 2008 27 6 809 12 10.1007/s10067-008-0842-z 18247080
Mäkitie AA, Törnwall J, Mäkitie O. Bisphosphonate treatment in craniofacial fibrous dysplasia—a case report and review of the literature. Clin Rheumatol. 2008;27(6):809–12.18247080
43. Valentini V Cassoni A Marianetti TM Terenzi V Fadda MT Iannetti G Craniomaxillofacial Fibrous Dysplasia: conservative treatment or radical surgery? A retrospective study on 68 patients Plast Reconstr Surg 2009 123 2 653 60 10.1097/PRS.0b013e318196bbbe 19182626
Valentini V, Cassoni A, Marianetti TM, Terenzi V, Fadda MT, Iannetti G. Craniomaxillofacial Fibrous Dysplasia: conservative treatment or radical surgery? A retrospective study on 68 patients. Plast Reconstr Surg. 2009;123(2):653–60.19182626
44. Posnick JC Fibrous dysplasia of the craniomaxillofacial region: current clinical perspectives Br J Oral Maxillofac Surg 1998 36 4 264 73 10.1016/S0266-4356(98)90710-0 9762454
Posnick JC. Fibrous dysplasia of the craniomaxillofacial region: current clinical perspectives. Br J Oral Maxillofac Surg. 1998;36(4):264–73.9762454
45. Alvares LC Capelozza ALA Cardoso CL Lima MC Fleury RN Damante JH Monostotic fibrous dysplasia: a 23-year follow-up of a patient with spontaneous bone remodeling. Oral surgery, oral medicine, oral Pathology Oral Radiol Endodontology 2009 107 2 229 34
Alvares LC, Capelozza ALA, Cardoso CL, Lima MC, Fleury RN, Damante JH. Monostotic fibrous dysplasia: a 23-year follow-up of a patient with spontaneous bone remodeling. Oral surgery, oral medicine, oral Pathology. Oral Radiol Endodontology. 2009;107(2):229–34.
